 - Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor e.g. Neulasta or 7 days for short-acting growth factor; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair 